医学
实施研究
过程管理
风险分析(工程)
工程管理
风险评估
梅德林
管理科学
项目评估
卫生服务研究
风险管理
知识管理
定性研究
运营管理
缩小
作者
Meredith Y. Smith,Viviana Nguyen,Rania Mouchantaf,Priya Bahri
出处
期刊:Drug Safety
[Adis, Springer Healthcare]
日期:2026-11-19
标识
DOI:10.1007/s40264-026-01751-w
摘要
BACKGROUND: New regulatory guidance from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) emphasizes understanding implementation context to integrate risk minimization programs into healthcare delivery. OBJECTIVE: To demonstrate how to conduct a contextual analysis pre-program implementation (for a formative evaluation) and post-implementation (for a summative evaluation). METHODS: Two programs were selected: (1) the existing risk minimization program for valproate in Europe and (2) the proposed Risk Mitigation and Evaluation Strategy (REMS) in the USA for tanezumab. Data sources included: (1) a collated set of written statements from stakeholders at the EMA's 2017 Public Hearing for valproate and (2) the 2021 FDA Advisory Committee meeting transcript for tanezumab. Both documents were analyzed qualitatively using codes from the Consolidated Framework for Implementation Research (CFIR). RESULTS: From the valproate document, 26 determinants were identified as having affected the implementation and delivery of the risk minimization program, the majority of which were clustered in the inner setting, individuals, and implementation process domains. From the tanezumab document, ten determinants were identified as having the potential to affect REMS implementation, the majority of which clustered in the innovation and individuals domains. In both cases, more barriers than facilitators were identified. CONCLUSIONS: Multiple factors operating at multiple socioecological levels were affecting or had the potential to affect risk minimization program implementation and delivery in the healthcare system. Implementation frameworks such as the CFIR provide a comprehensive and systematic way to identify relevant factors. Findings can be used to guide selection of appropriate strategies to reduce barriers and leverage facilitators.
科研通智能强力驱动
Strongly Powered by AbleSci AI